Acquisitions - Schedule Of Preliminary Allocation Of The Purchase Price (Details) - USD ($) $ in Thousands		9 Months Ended
	Jul. 08, 2025	Sep. 30, 2025	Dec. 31, 2024
ASSETS
Goodwill		$ 23,460	$ 0
Akoya Biosciences, Inc.
ASSETS
Cash and cash equivalents	$ 16,108
Accounts receivable, net of allowance for expected credit losses	8,616
Inventory	25,800
Prepaid expenses and other assets	5,483
Property and equipment, net	12,087
Intangible assets	121,800
Goodwill	23,460
Operating lease right-of-use assets	4,585
Finance lease right-of-use assets	1,041
Total assets acquired	218,980
Liabilities:
Accounts payable	8,266
Accrued expenses and other liabilities	34,206
Deferred revenue	18,879
Operating lease liabilities	5,616
Finance lease liabilities	1,040
Total liabilities assumed	68,007
Net assets acquired	$ 150,973
Weighted Average Useful Life (years)	9 years 7 months 6 days
Emission
ASSETS
Cash and cash equivalents		43
Accounts receivable, net of allowance for expected credit losses		49
Inventory		307
Intangible assets		12,900
Goodwill		6,374
Total assets acquired		19,673
Liabilities:
Accounts payable		57
Deferred tax liability		3,007
Total liabilities assumed		3,064
Net assets acquired		$ 16,609
Weighted Average Useful Life (years)		14 years